Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cactus Acquisition Corp. 1 LtdCCTSU · Entity 88589 | Director | October 28, 2021 | November 03, 2021 |
| MediWound Ltd.MDWD · Entity 296 | Director | June 03, 2026 | June 04, 2026 |
| STRATA Skin Sciences, Inc.SSKN · Entity 72980 | Director | July 05, 2023 | July 07, 2023 |
| Stereotaxis, Inc.STXS · Entity 6577 | Director | July 01, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cactus Acquisition Corp. 1 Ltd
Report date October 28, 2021 · Filed November 03, 2021
This filing explicitly reported no securities owned.
MediWound Ltd.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 55,815 |
Ending reported balance
After 2026-06-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-03 · Purchase · Acquired 175 · Balance 49,990 Row 2 · 2026-06-03 · Purchase · Acquired 5,825 · Balance 55,815 |
| Ordinary sharesSEC Table I · non-derivative | Direct | 1,200 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,200 F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Series A WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $13.48 · Expires 2026-11-28 | Direct | 16,336 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 16,336 |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.50 · Expires 2032-08-17 | Direct | 28,571 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 28,571 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $11.89 · Expires 2033-05-30 | Direct | 11,800 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 11,800 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.73 · Expires 2034-02-26 | Direct | 12,570 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 12,570 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $18.54 · Expires 2035-02-11 | Direct | 9,200 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 9,200 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $17.60 · Expires 2036-03-04 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 10,000 F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F3: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
F2: There were no transactions affected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
F3: The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest 100% on the one-year anniversary of the grant date.
STRATA Skin Sciences, Inc.
Report date July 05, 2023 · Filed July 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SSKN Common StockSEC Table I · non-derivative | Direct | 289,871 |
Reported balance
After 2023-07-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-07-05 · Grant · Acquired 38,835 · Balance 289,871 F1: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period.
Stereotaxis, Inc.
Report date July 01, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 179,327 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 43,103 · Balance 179,327 F1: Grant of restricted share units. Each restricted share unit represents a right to receive one share of common stock. The restricted share units vest on the earliest to occur of (i) the fifth anniversary of the date of the award, (ii) the date on which the service of the director on the board of directors terminates, or (iii) a Change of Control (as defined in the award documents). |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted share units. Each restricted share unit represents a right to receive one share of common stock. The restricted share units vest on the earliest to occur of (i) the fifth anniversary of the date of the award, (ii) the date on which the service of the director on the board of directors terminates, or (iii) a Change of Control (as defined in the award documents).
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COGENTIX MEDICAL INC /DE/
Report date April 23, 2018 · Filed April 23, 2018
Section 16 reporting ended · disclosed 2018-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-23 transaction · row 1
1 source rowRow 1 · 2018-04-23 · Disposition to issuer · Disposed 159,172 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement"), all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") were cancelled and converted into the right to receive a cash payment of $3.85 per share, net to the reporting person in cash, without interest and less any applicable withholding taxes (the "Merger Consideration") upon the effectiveness of the merger of Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement"), all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") were cancelled and converted into the right to receive a cash payment of $3.85 per share, net to the reporting person in cash, without interest and less any applicable withholding taxes (the "Merger Consideration") upon the effectiveness of the merger of Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC.
IsoPlexis Corp
Report date March 21, 2023 · Filed March 21, 2023
Section 16 reporting ended · disclosed 2023-03-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 1
1 source rowRow 1 · 2023-03-21 · Disposition to issuer · Disposed 50,253 · Balance 0 F1: On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each share of common stock, par value $0.001, of IsoPlexis (IsoPlexis Common Stock) reported in this Form 4 was converted into the right to receive 0.6120 fully paid and nonassessable shares of common stock, par value $0.00005, of Berkeley Lights (Berkeley Lights Common Stock), together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any, and any unpaid dividends or other distributions. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2032-08-22 | Direct | 0 |
Reported balance
After 2023-03-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-21 · Disposition to issuer · Disposed 196,842 · Balance 0 F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option reported in this Form 4 that was (a) vested and unexercised or (b) vested solely as a result of the consummation of the merger pursuant to the Merger Agreement was, in each case, exercisable prior to the effective time of such merger and, to the extent unexercised at such effective time, canceled for no consideration. F3: Vests in 36 equal monthly installments from the grant date (August 22, 2022) |
Filing footnotes · ownership attribution and instrument terms
F1: On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each share of common stock, par value $0.001, of IsoPlexis (IsoPlexis Common Stock) reported in this Form 4 was converted into the right to receive 0.6120 fully paid and nonassessable shares of common stock, par value $0.00005, of Berkeley Lights (Berkeley Lights Common Stock), together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any, and any unpaid dividends or other distributions.
F2: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option reported in this Form 4 that was (a) vested and unexercised or (b) vested solely as a result of the consummation of the merger pursuant to the Merger Agreement was, in each case, exercisable prior to the effective time of such merger and, to the extent unexercised at such effective time, canceled for no consideration.
F3: Vests in 36 equal monthly installments from the grant date (August 22, 2022)
LUMINEX CORP
Report date July 14, 2021 · Filed July 15, 2021
Section 16 reporting ended · disclosed 2021-07-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2021-07-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-07-14 · Disposition to issuer · Disposed 152,372 · Balance 88,798 F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share. F2: This amount includes 515 shares obtained under the Luminex Corporation Employee Stock Purchase Plan on May 31, 2021. Row 2 · 2021-07-14 · Disposition to issuer · Disposed 88,798 · Balance 0 F3: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock which were outstanding as of immediately prior to the Effective Time fully vested and became unrestricted common stock, and each such share of common stock that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes). |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.13 · Expires 2023-03-22 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-14 · Disposition to issuer · Disposed 177,880 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.13 · Expires 2023-03-22 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-14 · Disposition to issuer · Disposed 106,728 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.04 · Expires 2024-03-10 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-14 · Disposition to issuer · Disposed 334,896 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.98 · Expires 2025-03-12 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-14 · Disposition to issuer · Disposed 140,815 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
| Stock Option (Right To Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.09 · Expires 2027-03-12 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-07-14 · Disposition to issuer · Disposed 648,686 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $24.43 · Expires 2026-03-12 | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-14 · Disposition to issuer · Disposed 129,520 · Balance 0 F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share.
F2: This amount includes 515 shares obtained under the Luminex Corporation Employee Stock Purchase Plan on May 31, 2021.
F3: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock which were outstanding as of immediately prior to the Effective Time fully vested and became unrestricted common stock, and each such share of common stock that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes).
F4: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 1, 2026 20:00 UTC | Stereotaxis, Inc. STXS · Entity 6577 | GrantCommon Stock | 43,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-031537 · ownership.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,327 F1 · shares: Grant of restricted share units. Each restricted share unit represents a right to receive one share of common stock. The restricted share units vest on the earliest to occur of (i) the fifth anniversary of the date of the award, (ii) the date on which the service of the director on the board of directors terminates, or (iii) a Change of Control (as defined in the award documents). Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:05 UTC | MediWound Ltd. MDWD · Entity 296 | PurchaseOrdinary Shares | 5,825 | $14.00 | $81,550.00 |
DisclosureSEC source: 0001178913-26-003106 · zk2635499.xml · nonDerivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,815 Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:05 UTC | MediWound Ltd. MDWD · Entity 296 | PurchaseOrdinary Shares | 175 | $13.98 | $2,445.63 |
DisclosureSEC source: 0001178913-26-003106 · zk2635499.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,990 Read SEC document |
| January 02, 2026 Filed Jan 2, 2026 21:15 UTC | Stereotaxis, Inc. STXS · Entity 6577 | GrantCommon Stock | 46,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-000116 · ownership.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,224 F1 · shares: Grant of restricted share units. Each restricted share unit represents a right to receive one share of common stock. The restricted share units vest on the earliest to occur of (i) the fifth anniversary of the date of the award, (ii) the date on which the service of the director on the board of directors terminates, or (iii) a Change of Control (as defined in the award documents). Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:05 UTC | Stereotaxis, Inc. STXS · Entity 6577 | GrantCommon Stock | 43,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-017788 · ownership.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,276 F1 · shares: Grant of restricted share units. Each restricted share unit represents a right to receive one share of common stock. The restricted share units vest on the earliest to occur of (i) the fifth anniversary of the date of the award, (ii) the date on which the service of the director on the board of directors terminates, or (iii) a Change of Control (as defined in the award documents). Read SEC document |
| January 02, 2025 Filed Jan 2, 2025 22:30 UTC | Stereotaxis, Inc. STXS · Entity 6577 | GrantCommon Stock | 45,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-000096 · ownership.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,608 F1 · shares: Grant of restricted share units. Each restricted share unit represents a right to receive one share of common stock. The restricted share units vest on the earliest to occur of (i) the fifth anniversary of the date of the award, (ii) the date on which the service of the director on the board of directors terminates, or (iii) a Change of Control (as defined in the award documents). Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 16:07 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 38,835 | $1.03 | $40,000.05 |
DisclosureSEC source: 0001051514-23-000030 · form4.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 289,871 F1 · security: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 5, 2023, utilizing the closing price on July 3, 2023. The Restricted Stock will vest at 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:41 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerStock Option · Derivative | 196,842 | Not disclosed Strike: $1.90 | Not disclosed |
DisclosureSEC source: 0001062993-23-007393 · form4.xml · derivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 196,842 shares Expires 2032-08-22 F2 · price: On March 21, 2023, pursuant to the Merger Agreement, each IsoPlexis stock option reported in this Form 4 that was (a) vested and unexercised or (b) vested solely as a result of the consummation of the merger pursuant to the Merger Agreement was, in each case, exercisable prior to the effective time of such merger and, to the extent unexercised at such effective time, canceled for no consideration. F3 · derivative.exercise_date: Vests in 36 equal monthly installments from the grant date (August 22, 2022) Read SEC document |
| March 21, 2023 Filed Mar 21, 2023 20:41 UTC | IsoPlexis Corp ISO · Entity 115290 | Disposition to issuerCommon Stock | 50,253 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-23-007393 · form4.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On March 21, 2023, pursuant to the Agreement and Plan of Merger, dated as of December 21, 2022 (the Merger Agreement), by and among IsoPlexis Corporation, a Delaware corporation (IsoPlexis), Berkeley Lights, Inc., a Delaware corporation (Berkeley Lights), and Iceland Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Berkeley Lights, each share of common stock, par value $0.001, of IsoPlexis (IsoPlexis Common Stock) reported in this Form 4 was converted into the right to receive 0.6120 fully paid and nonassessable shares of common stock, par value $0.00005, of Berkeley Lights (Berkeley Lights Common Stock), together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any, and any unpaid dividends or other distributions. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 13:49 UTC | IsoPlexis Corp ISO · Entity 115290 | PurchaseCommon Stock | 40,000 | $1.94 | $77,728.00 |
DisclosureSEC source: 0001062993-22-018931 · form4.xml · nonDerivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,253 Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 13:49 UTC | IsoPlexis Corp ISO · Entity 115290 | PurchaseCommon Stock | 10,253 | $1.89 | $19,384.32 |
DisclosureSEC source: 0001062993-22-018931 · form4.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,253 Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 13:26 UTC | IsoPlexis Corp ISO · Entity 115290 | GrantStock Option · Derivative | 196,842 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001062993-22-018693 · form4.xml · derivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,842 Underlying: Common Stock · 196,842 shares Expires 2032-08-22 F1 · derivative.exercise_date: Time-vesting option vesting in 36 equal monthly installments. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 16:07 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 43,244 | $0.93 | $40,000.70 |
DisclosureSEC source: 0001051514-22-000076 · form4.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,036 F1 · security: Represents Restricted Stock Units issued to the recipient in lieu of a portion of the recipient's Board Compensation on July 1, 2022. The Restricted Stock Units will vest at 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 8,488 | $1.48 | $12,562.24 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 14 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,792 Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 10,717 | $1.48 | $15,807.58 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 13 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,304 Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 21,579 | $1.47 | $31,721.13 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 12 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,587 Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 100 | $1.47 | $146.50 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 11 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,008 Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 2,382 | $1.46 | $3,477.72 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 10 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,908 Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 1,542 | $1.45 | $2,235.90 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 9 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,526 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 407 | $1.45 | $590.15 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 8 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,984 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 30 | $1.44 | $43.20 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 7 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,577 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 5,112 | $1.43 | $7,310.16 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 6 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,547 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 50 | $1.43 | $71.25 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 5 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,435 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 9,807 | $1.42 | $13,925.94 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 4 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,385 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 9,270 | $1.41 | $13,070.70 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 3 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,578 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 781 | $1.41 | $1,097.31 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,308 Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 16:18 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseSSKN Common Stock | 1,155 | $1.40 | $1,617.00 |
DisclosureSEC source: 0001051514-21-000064 · form4.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,527 Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 17:32 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 28,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001051514-21-000036 · form4.xml · nonDerivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,372 F1 · security: Represents Restricted Stock Units issued to the recipient, in lieu of a portion of the recipient's Board Compensation, on July 20, 2021. The Restricted Stock Units generally vest at 100% on the first anniversary of the date of grant. RSUs have a minimum one year vesting unless as permitted under Section 7.3(c). Read SEC document |
| July 20, 2021 Filed Jul 21, 2021 17:32 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSSKN Common Stock | 32,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001051514-21-000036 · form4.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,595 Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:59 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 648,686 | $23.09 Strike: $23.09 | $14,978,159.74 |
DisclosureSEC source: 0001033905-21-000056 · wf-form4_162637913603379.xml · derivative · entry 8 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 648,686 shares Expires 2027-03-12 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:59 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerCommon Stock · Derivative | 129,520 | $24.43 Strike: $24.43 | $3,164,173.60 |
DisclosureSEC source: 0001033905-21-000056 · wf-form4_162637913603379.xml · derivative · entry 7 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 129,520 shares Expires 2026-03-12 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:59 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 140,815 | $21.98 Strike: $21.98 | $3,095,113.70 |
DisclosureSEC source: 0001033905-21-000056 · wf-form4_162637913603379.xml · derivative · entry 6 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,815 shares Expires 2025-03-12 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:59 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 334,896 | $18.04 Strike: $18.04 | $6,041,523.84 |
DisclosureSEC source: 0001033905-21-000056 · wf-form4_162637913603379.xml · derivative · entry 5 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 334,896 shares Expires 2024-03-10 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:59 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 106,728 | $19.13 Strike: $19.13 | $2,041,706.64 |
DisclosureSEC source: 0001033905-21-000056 · wf-form4_162637913603379.xml · derivative · entry 4 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106,728 shares Expires 2023-03-22 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:59 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerStock Option (Right To Buy) · Derivative | 177,880 | $19.13 Strike: $19.13 | $3,402,844.40 |
DisclosureSEC source: 0001033905-21-000056 · wf-form4_162637913603379.xml · derivative · entry 3 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 177,880 shares Expires 2023-03-22 F4 · shares: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. F4 · price: Disposed of pursuant to the Merger Agreement, whereby each stock option outstanding as of immediately prior to the Effective Time fully vested and was cancelled at the Effective Time and converted into the right to receive a total amount in cash, equal to the product of (x) the excess, if any, of $37.00 over the exercise price per share of each stock option (without interest and subject to deduction for any required withholding taxes) and (y) the number of shares underlying such stock option. If the amount that could have been obtained upon the exercise of the stock option pursuant to the foregoing is equal to or less than zero, then the option was terminated without payment. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:59 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerCommon Stock | 88,798 | $37.00 | $3,285,526.00 |
DisclosureSEC source: 0001033905-21-000056 · wf-form4_162637913603379.xml · nonDerivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · shares: Disposed of pursuant to the Merger Agreement, whereby unvested shares of restricted stock which were outstanding as of immediately prior to the Effective Time fully vested and became unrestricted common stock, and each such share of common stock that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes). Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 15:59 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerCommon Stock | 152,372 | $37.00 | $5,637,764.00 |
DisclosureSEC source: 0001033905-21-000056 · wf-form4_162637913603379.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,798 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share. F2 · shares: This amount includes 515 shares obtained under the Luminex Corporation Employee Stock Purchase Plan on May 31, 2021. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 16:52 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantStock Option (Right To Buy) · Derivative | 648,686 | $23.09 Strike: $23.09 | $14,978,159.74 |
DisclosureSEC source: 0001033905-21-000020 · wf-form4_161584151522819.xml · derivative · entry 4 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,686 Underlying: Common Stock · 648,686 shares Expires 2027-03-12 F4 · shares: The Board of Directors of Luminex Corporation determined the level of performance and number of shares earned for this performance option. The option will vest annually in four equal installments beginning 03/12/21. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 16:52 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 61,050 | $32.76 | $1,999,998.00 |
DisclosureSEC source: 0001033905-21-000020 · wf-form4_161584151522819.xml · nonDerivative · entry 3 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,655 F3 · balance_after: This balance includes 395 shares obtained on November 30, 2020 under the Luminex Corporation Employee Stock Purchase Plan. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 16:52 UTC | LUMINEX CORP LMNX · Entity 137318 | Tax withholdingCommon Stock | 7,696 | $32.76 | $252,120.96 |
DisclosureSEC source: 0001033905-21-000020 · wf-form4_161584151522819.xml · nonDerivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,210 F2 · shares: This disposition relates to withholding for taxes on 19,560 vesting shares associated with a previously reported issuance. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:52 UTC | LUMINEX CORP LMNX · Entity 137318 | Tax withholdingCommon Stock | 2,726 | $32.45 | $88,458.70 |
DisclosureSEC source: 0001033905-21-000020 · wf-form4_161584151522819.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,906 F1 · shares: This disposition relates to withholding for taxes on 6,929 vesting shares associated with a previously reported issuance. Read SEC document |
| August 05, 2020 Filed Aug 5, 2020 18:56 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionStock Option (Right To Buy) · Derivative | 8,559 | $15.93 Strike: $15.93 | $136,344.87 |
DisclosureSEC source: 0001033905-20-000116 · wf-form4_159666817455334.xml · derivative · entry 9 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,559 shares Expires 2022-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 5, 2020 18:56 UTC | LUMINEX CORP LMNX · Entity 137318 | SaleCommon Stock | 8,559 | $40.16 | $343,729.44 |
DisclosureSEC source: 0001033905-20-000116 · wf-form4_159666817455334.xml · nonDerivative · entry 6 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,632 F1 · shares: This sale is being made pursuant to a trading plan intended to comply with Rule 10b5-1 adopted by the seller on May 26, 2020. The representation regarding the seller's knowledge of material adverse non-public information speaks as of the date that the aforementioned trading plan was adopted. F2 · balance_after: This balance includes 608 shares obtained under the Luminex Corporation Employee Stock Purchase Plan on May 29, 2020. Read SEC document |
| August 05, 2020 Filed Aug 5, 2020 18:56 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionCommon Stock | 8,559 | $15.93 | $136,344.87 |
DisclosureSEC source: 0001033905-20-000116 · wf-form4_159666817455334.xml · nonDerivative · entry 5 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 18:56 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionStock Option (Right To Buy) · Derivative | 116,441 | $15.93 Strike: $15.93 | $1,854,905.13 |
DisclosureSEC source: 0001033905-20-000116 · wf-form4_159666817455334.xml · derivative · entry 8 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,559 Underlying: Common Stock · 116,441 shares Expires 2022-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 18:56 UTC | LUMINEX CORP LMNX · Entity 137318 | SaleCommon Stock | 116,441 | $39.50 | $4,599,419.50 |
DisclosureSEC source: 0001033905-20-000116 · wf-form4_159666817455334.xml · nonDerivative · entry 4 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,024 F1 · shares: This sale is being made pursuant to a trading plan intended to comply with Rule 10b5-1 adopted by the seller on May 26, 2020. The representation regarding the seller's knowledge of material adverse non-public information speaks as of the date that the aforementioned trading plan was adopted. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 18:56 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionCommon Stock | 116,441 | $15.93 | $1,854,905.13 |
DisclosureSEC source: 0001033905-20-000116 · wf-form4_159666817455334.xml · nonDerivative · entry 3 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 18:56 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionStock Option (Right To Buy) · Derivative | 125,000 | $15.93 Strike: $15.93 | $1,991,250.00 |
DisclosureSEC source: 0001033905-20-000116 · wf-form4_159666817455334.xml · derivative · entry 7 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2022-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 18:56 UTC | LUMINEX CORP LMNX · Entity 137318 | SaleCommon Stock | 125,000 | $38.51 | $4,813,137.50 |
DisclosureSEC source: 0001033905-20-000116 · wf-form4_159666817455334.xml · nonDerivative · entry 2 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,024 F1 · shares: This sale is being made pursuant to a trading plan intended to comply with Rule 10b5-1 adopted by the seller on May 26, 2020. The representation regarding the seller's knowledge of material adverse non-public information speaks as of the date that the aforementioned trading plan was adopted. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 18:56 UTC | LUMINEX CORP LMNX · Entity 137318 | Exercise / conversionCommon Stock | 125,000 | $15.93 | $1,991,250.00 |
DisclosureSEC source: 0001033905-20-000116 · wf-form4_159666817455334.xml · nonDerivative · entry 1 SHAMIR NACHUM · CIK 0001622164 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.